Y-Mabs Therapeutics Inc

Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. Its services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Y-Mabs Therapeutics reports record revenues and strategic growth initiatives

Y-Mabs Therapeutics demonstrated strong financial performance in Q4 2022, with record revenues and effective cost management.
The company's focus on product development and market expansion, coupled with strategic restructuring, positions it for sustainable growth.
While facing financial challenges and competitive pressures, Y-Mabs Therapeutics has opportunities for portfolio expansion and market penetration.

Y-Mabs Therapeutics Inc achieves record revenue, eyes international expansion

Y-Mabs Therapeutics Inc reported strong performance in Q1 2023, driven by record net product revenue and positive sales trends for DANYELZA.
The company's focus on R&D, commercialization efforts, and strategic partnerships positions it well for future growth and market expansion.
While facing challenges such as market competition and restructuring, Y-Mabs Therapeutics Inc has opportunities to capitalize on its innovative technologies and market presence.
With updated financial guidance and a clear roadmap for product development, the company is poised for continued success and revenue growth in 2023.

Y-Mabs reports robust Q2 earnings, eyes international expansion and label growth

Y-Mabs Therapeutics Inc demonstrated strong financial performance with notable revenue growth for DANYELZA and advancements in their SADA platform.
While facing challenges in competitive dynamics and treatment optimization, the company is strategically positioned for international market expansion and revenue diversification.
Opportunities lie in market penetration strategies, upcoming label expansions, and continued product development efforts, indicating a positive outlook for future growth and innovation.

Y-Mabs Therapeutics reports strong Q3 performance and eyes oncology expansion

Y-Mabs Therapeutics showcased robust financial performance, strong commercial traction for DANYELZA, and promising advancements in the SADA platform.
While facing challenges in scalability and dose optimization, the company's strategic strengths lie in leadership changes, clinical progress, and market penetration.
Opportunities for growth include expanding indications, optimizing treatment protocols, and enhancing visibility through data presentations and partnerships.

Y-mAbs reports strong Q4 earnings, eyes global expansion and program innovations

Y-mAbs Therapeutics showcased robust financial performance in Q4 2023, driven by strong DANYELZA net product sales and revenue growth.
Effective cost management, expansion plans into key markets, and enhanced marketing efforts position the company for continued success.
While facing challenges in managing expenses and addressing analyst inquiries, Y-mAbs has opportunities for growth through international expansion and program innovations.

Y-mAbs reports record DANYELZA sales, eyes global expansion and innovation

Y-mAbs Therapeutics showcased robust financial performance with record DANYELZA sales, underpinned by strategic expansion efforts and progress in clinical programs.
While facing questions on growth strategies and potential seasonality challenges, the company's strong balance sheet and focus on innovation position it well for future success.
By emphasizing responsible capital allocation, global expansion, and advancements in cancer treatment options, Y-mAbs is poised to navigate challenges and seize opportunities for sustained growth.

Y-mAbs Therapeutics reports revenue growth and promising clinical outcomes

Y-mAbs Therapeutics Inc. delivered solid financial performance, strong product sales, and promising clinical trial outcomes in Q2 2024, positioning the company for continued growth.
While facing challenges in managing cash burn and sustaining revenue growth, the company's commitment to innovation and patient care presents opportunities for future success.
With a revised revenue guidance and focus on advancing novel therapies, Y-mAbs Therapeutics Inc. remains dedicated to improving patient lives and driving growth in the biopharmaceutical sector.

Y-Mabs Therapeutics reports mixed Q3 performance with growth opportunities

Y-Mabs Therapeutics faced challenges with declining DANYELZA revenues outside the U.S.
However, the company demonstrated strengths in securing long-term exclusivity and expanding market reach.
Opportunities lie in leveraging partnerships, exploring new targets, and ongoing clinical trials.
Maintaining financial stability and meeting full-year guidance are key priorities for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK, Dec. 07, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the presentation of CD38-SADA in Non-Hodgkin Lymphoma (NHL) preclinical data and trial in progress posters at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition being held on December 7 –10, 2024, in San Diego, California.

Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting

NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that it will participate in Citi's 2024 Global Healthcare Conference. Members of the Y-mAbs management team will host one-on-one meetings at the conference on Wednesday, December 4, 2024 in Miami, FL.

Y-mAbs to Participate at Citi's 2024 Global Healthcare Conference

Y-mAbs Therapeutics, Inc. (YMAB) Q3 2024 Earnings Call Transcript

Y-mAbs Therapeutics, Inc. (YMAB) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.18 per share a year ago.

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Lags Revenue Estimates

NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today reported financial results for the third quarter ended September 30, 2024.

Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate Developments

NEW YORK, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, and Nobelpharma Co., Ltd. today announced that they have entered into an exclusive license and distribution agreement for the development and commercialization in Japan of DANYELZA for the treatment of patients with relapsed/refractory high-risk neuroblastoma and, upon agreement by the parties, potentially relapsed osteosarcoma.

Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) in Japan

YmAbs Therapeutics (YMAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Y-mAbs Therapeutics, Inc. (YMAB) Report Negative Earnings Next Week? What You Should Know

NEW YORK, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will report third quarter 2024 financial and operating results before the market open on Friday, November 8, 2024. The Company will hold a conference call and webcast to discuss these results at 8:00 a.m. ET.

Y-mAbs Announces Third Quarter 2024 Conference Call and Webcast

NEW YORK, Oct. 01, 2024 (GLOBE NEWSWIRE) --  Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that its management team will participate in the following upcoming investor conferences:

Y-mAbs to Participate in Upcoming Investor Conferences in October

NEW YORK, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced new clinical and preclinical data from studies evaluating naxitamab and GD2-SADA, respectively, in neuroblastoma. The results are summarized in poster presentations scheduled to be presented September 6 – 7, 2024, at the American Academy of Cancer Research (“AACR”) Special Conference in the Advances in Pediatric Cancer Research in Toronto, Canada.

Y-mAbs Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform at AACR Special Conference on Advances in Pediatric Cancer Research

NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that Michael Rossi, President and Chief Executive Officer, will present at the following upcoming investor conferences:

Y-mAbs to Participate in Upcoming Investor Conferences in September

The commercial-stage biotech took the wraps off its second-quarter results. Revenue was up on a year-over-year basis, but it fell short of analyst estimates -- as did net loss.

Why Y-mAbs Therapeutics Stock Got Mashed on Monday

YMAB maintains a market valuation around $500 million, potential for substantial appreciation. Pipeline updates include expanding the naxitamab market and progressing SADA radioimmunotherapeutic. Financially, YMAB has $77.8 million in cash, growing product revenues, and a cash runway of 8-9 quarters.

Revisiting Y-mAbs After The Summer Oncology Meeting (Rating Upgrade)

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB ) Q2 2024 Earnings Conference Call August 12, 2024 8:00 AM ET Company Participants Courtney Dugan - Head-IR Michael Rossi - President & CEO Sue Smith - Chief Commercial Officer Vignesh Rajah - Chief Medical Officer Peter Pfreundschuh - CFO Conference Call Participants Etzer Darout - BMO Capital Markets Nicole Germino - Truist Securities Justin Walsh - JonesTrading Alec Stranahan - Bank of America Michael Ulz - Morgan Stanley John Newman - Canaccord Genuity Operator Good morning, and welcome to Y-mAbs Therapeutics Inc.'s Earnings Conference Call for the Second Quarter of 2024. At this time, all participants are in a listen-only mode.

Y-mAbs Therapeutics, Inc. (YMAB) Q2 2024 Earnings Call Transcript

Y-mAbs Therapeutics, Inc. (YMAB) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.14 per share a year ago.

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Misses Revenue Estimates

NEW YORK, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2024.

Y-mAbs Reports Second Quarter 2024 Financial Results and Recent Corporate Developments

NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced its management team will participate in the following upcoming investor conferences:

Y-mAbs to Participate in Upcoming Investor Conferences in August

NEW YORK, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will report second quarter 2024 financial and operating results before market open on Monday, August 12, 2024. The Company will hold a conference call and webcast to discuss these results at 8:00 a.m. ET.

Y-mAbs Announces Second Quarter 2024 Conference Call and Webcast

NEW YORK, July 22, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that the United States District Court for the Southern District of New York has approved the following announcement of a proposed class action settlement that would benefit purchasers of stock of Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB):

Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Stock of Y-mAbs Therapeutics, Inc. - YMAB

NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Peter Pfreundschuh as Chief Financial Officer, effective June 28, 2024. Mr. Pfreundschuh will report to Mike Rossi, President and Chief Executive Officer.

Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer

PHILADELPHIA, PA / ACCESSWIRE / June 14, 2024 / Kaskela Law LLC announces that it is investigating Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) ("Y-mAbs") on behalf of the company's long-term shareholders. Recently an amended securities fraud complaint was filed against Y-mAbs on behalf of certain investors who purchased shares of the company's stock between October 6, 2020, and October 28, 2022.

Y-MABS SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Y-mAbs Therapeutics, Inc. (YMAB) on Behalf of the Company's Long-Term Shareholders and Encourages Investors to Contact the Firm

NEW YORK, June 07, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that preclinical GD2-SADA data will be presented at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2024 Annual Meeting taking place June 8 – 11, 2024, in Toronto, Canada.

Y-mAbs Announces Preclinical GD2-SADA Data to be Presented at 2024 SNMMI Annual Meeting

NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Norman LaFrance, M.D. as Chief Development Officer.

Y-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development Officer

NEW YORK, June 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the publication of preclinical GD2-SADA data at the 2024 American Society of Clinical Oncology (“ASCO”) Annual Meeting, taking place May 31 through June 4, 2024, in Chicago, IL.

Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting

NEW YORK, June 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced new interim data from the Phase 2 Trial 201 of naxitamab in combination with granulocyte-macrophage colony-stimulating factor (“GM-CSF”) in patients with relapsed or refractory high-risk neuroblastoma with residual disease limited to bone and/or bone marrow. The results are summarized in poster presentations scheduled to be presented today, June 1, 2024, at the 2024 American Society of Clinical Oncology (“ASCO”) Annual Meeting in Chicago, IL.

News for Y-Mabs Therapeutics Inc Stock (YMAB)